What did Neurizon Therapeutics (ASX:NUZ) recently announce regarding its ALS treatment?

Neurizon Therapeutics received formal ethics approval from the Bellberry Human Research Ethics Committee to begin a Phase 1 clinical study for a new oral liquid version of its lead candidate, NUZ-001.

Why is a liquid formulation of NUZ-001 important for the company’s strategy?

The liquid version specifically targets a major pain point for patients with Amyotrophic Lateral Sclerosis (ALS) who suffer from dysphagia, or difficulty swallowing.

What are the key details of the upcoming Phase 1 study for NUZ-001?

The Australian-based trial will enroll 32 healthy volunteers in a randomized, four-arm study. Researchers will compare how the body processes the drug (pharmacokinetics) in both liquid and tablet forms under fed and fasted conditions.

How does this new study fit into Neurizon Therapeutics’ (ASX:NUZ) broader clinical timeline?

This Phase 1 liquid formulation trial runs parallel to NUZ-001’s ongoing Phase 2/3 evaluation in the HEALEY ALS Platform Trial in the United States.

What is the current financial standing of Neurizon Therapeutics (ASX:NUZ)?

The company recently strengthened its balance sheet by raising $2.7 million through a shortfall placement. This capital injection is intended to fund the upcoming clinical trials and maintain development momentum during a period of corporate transition.

Neurizon secures ethics approval for ALS liquid study

Written by Isaac FrancisPublished May. 13 2026Last Updated May. 13 2026

Neurizon Therapeutics (ASX:NUZ) has secured formal ethics approval from the Bellberry Human Research Ethics Committee to commence a Phase 1 clinical study of its NUZ-001 oral liquid formulation.

The regulatory milestone represents a strategic effort to enhance treatment accessibility for patients battling amyotrophic lateral sclerosis, a condition where progressive dysphagia—or swallowing difficulty—often hinders traditional tablet administration.

The upcoming Australian-based study will involve 32 healthy volunteers in a randomised, four-arm trial designed to compare the pharmacokinetic profile, safety, and tolerability of the liquid formulation against the existing tablet form under various dietary conditions.

Beyond physiological data, the trial will assess the liquid’s palatability and explore key biomarkers, with initiation slated for Q3 2026 and completion expected by the year's end.

This formulation programme runs parallel to Neurizon’s participation in the prestigious HEALEY ALS Platform Trial in the United States, where NUZ-001 is undergoing Phase 2/3 evaluation.

Preclinical data have already demonstrated the candidate's ability to penetrate the blood-brain barrier and stimulate neuronal protein clearance pathways essential for neuroprotection.

To support these clinical ambitions, the company recently secured $2.7 million in capital through a shortfall placement.

While navigating a leadership transition following the departure of CEO Dr Michael Thurn, interim executive chair Sergio Duchini remains focused on maintaining this clinical momentum, ensuring that the transition to more patient-friendly delivery systems remains a core priority for the firm’s development pipeline.

At the time of reporting, Neurizon Therapeutics’ share price was $0.070.